Recently, Salubris received the "Clinical Trial Approval Notice" approved and issued by NMPA, granting approval to conduct clinical trials for its independently developed innovative small molecule drug SAL0139 tablets (Project Code: SAL0139) for the treatment of hyperlipidemia [1].
Hyperlipidemia is an insidious metabolic disorder that poses a significant public health risk. Uncontrolled progression of the condition can result in multi-system complications. The accumulation of LDL-C-related cholesterol is a well-established key risk factor for the development of cardiovascular and cerebrovascular diseases [2].
Preclinical studies have shown that SAL0139 has the potential to reduce low-density lipoprotein cholesterol (LDL-C). If successfully developed and approved for marketing, this drug will provide a new treatment option for patients with hyperlipidemia. It will further enrich the company's portfolio of innovative products in the chronic disease areas, enhance the solutions for cardiovascular and cerebrovascular chronic disease treatment, and strengthen its overall competitiveness in this field.
References:
[1] Shenzhen Salubris Pharmaceuticals Co., Ltd. Announcement on SAL0139 Obtaining Clinical Trial Approval Notice
[2] Chinese Guidelines for Lipid Management (Primary Care Edition 2024)
Disclaimer:
This material is intended to provide knowledge in the field of disease, enhance disease awareness, and is not for promotional purposes.
The information contained herein is for reference only. Please follow the advice or guidance of physicians or other healthcare professionals.
丨About Salubris
Shenzhen Salubris Pharmaceuticals Co., Ltd., founded in 1998, is an innovation-driven pharmaceutical listed company (Stock Code: 002294) with integrated R&D, production, and marketing operations, rooted in China and serving the global market. With the mission of "providing exceptional pharmaceutical products for human health," Salubris has deepened its expertise in chronic disease treatment with a focus on cardiovascular and cerebrovascular conditions. The company has successfully commercialized alisartan monotherapy, combination drugs, and co-crystal formulations to address diverse complex hypertension challenges, establishing a unique family of first-in-class antihypertensive therapies centered on alisartan.
